Sign In

Communications of the ACM

ACM TechNews

FDA Issues Brain-Computer Interface Draft Guidance


View as: Print Mobile App Share: Send by email Share on reddit Share on StumbleUpon Share on Hacker News Share on Tweeter Share on Facebook
Logo of the Cybathlon Brain-Computer Interface Race.

The U.S. Food and Drug Administration has issued a new draft guidance to encourage development of a new generation of implantable brain-computer interface devices.

Credit: Cybathlon

The U.S. Food and Drug Administration (FDA) has issued a new draft guidance to encourage development of a new generation of implantable brain-computer interface (BCI) devices, to help patients suffering from paralysis or missing limbs regain mobility.

FDA commissioner Scott Gottlieb said the draft guidance's release was prompted by a recent public workshop, which defined BCI devices as "neuroprostheses that interface with the central or peripheral nervous system to restore lost motor or sensory capabilities."

The FDA said the guidance suggests non-clinical device testing can be used to demonstrate mitigation of potential risks prior to clinical tests.

Said Gottlieb, "Proper design of clinical trials is essential to provide reasonable assurance of safety and effectiveness to support a regulatory submission to the FDA."

From U.S. Food and Drug Administration
View Full Article

 

Abstracts Copyright © 2019 SmithBucklin, Washington, DC, USA


 

No entries found

Sign In for Full Access
» Forgot Password? » Create an ACM Web Account
ACM Resources